RAPT Therapeutics Files 8-K on Leadership and Compensation Changes
| Field | Detail |
|---|---|
| Company | Rapt Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, board-of-directors
TL;DR
RAPT Therapeutics filed an 8-K on 6/23/25 covering board and exec comp changes.
AI Summary
On June 23, 2025, RAPT Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated, though specific details on new appointments or compensation figures are not provided in this excerpt.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or new directions, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect company strategy and performance.
Key Numbers
- 001-38997 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-3313701 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- RAPT Therapeutics, Inc. (company) — Registrant
- June 23, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 561 Eccles Avenue, South San Francisco, CA 94080 (address) — Principal Executive Offices
- FLX Bio, Inc. (company) — Former Company Name
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors', but the specific names of departing or newly elected directors are not detailed in this excerpt.
What are the details of the new compensatory arrangements for officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' but does not provide specific details or dollar amounts for these arrangements in the provided text.
When was RAPT Therapeutics, Inc. formerly known as FLX Bio, Inc.?
The date of the name change from FLX Bio, Inc. to RAPT Therapeutics, Inc. was May 4, 2016.
What is the principal business address of RAPT Therapeutics, Inc.?
The principal executive offices are located at 561 Eccles Avenue, South San Francisco, California, 94080.
What is the filing date of this 8-K report?
The report was filed as of June 23, 2025, and the earliest event reported is also dated June 23, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding RAPT Therapeutics, Inc..